Lentinan

Lentinan

Clinical data
Synonyms	(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxyoxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
AHFS/Drugs.com	International Drug Names
ATC code	L03AX01 (WHO)
Identifiers
IUPAC name β-D-glucopyranosyl-(1→6)-[β-D-glucopyranosyl-(1→3)-[β-D-glucopyranosyl-(1→6)]-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)β-D-glucopyranosyl-(1→3)]-β-D-glucopyranose
CAS Number	37339-90-5 Y
PubChem CID	37723
ChemSpider	NA N
KEGG	D01695 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C42H72O36
Molar mass	1152.99948 g/mol
NY (what is this?)  (verify)

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview[edit | edit source]

Lentinan is an intravenous anti-tumor polysaccharide isolated from the fruit body of shiitake (Lentinula edodes). Lentinan has been approved as an adjuvant for stomach cancer in Japan since 1985.[2] Lentinan is one of the host-mediated anti-cancer drugs which has been shown to affect host defense immune systems.

Chemistry[edit | edit source]

Lentinan is a β-1,3 beta-glucan with β-1,6 branching. Molecular weight of lentinan is 500,000 Da. Specific rotation +14-22° (NaOH).

Research[edit | edit source]

An in vitro experiment showed lentinan stimulated production of white blood cells in the human cell line U937.^[1] A pharmacological blend (MC-S) of lentinan, PSK, Ganoderma lucidum and Astragalus propinquus has also been shown to stimulate white blood cell production in vitro.^[2]

An in vivo experiment on mice, revealed lentinan is orally active (since clinical use of the drug is administered through an IV).^[3]

Limited clinical studies of cancer patients have associated lentinan with a higher survival rate, higher quality of life, and lower re-occurrence of cancer.^{[4][5][6][7][8][9][10][11]}

Formulations containing Lentinan[edit | edit source]

Lentinex is a formulation featuring lentinan and is approved as a safe novel food in the EU.^[12]

References[edit | edit source]

1. ↑ Sia GM, Candlish JK. (Mar 1999). "Effects of shiitake (Lentinus edodes) extract on human neutrophils and the U937 monocytic cell line". Phytother Res. 13 (2): 133–7. doi:10.1002/(SICI)1099-1573(199903)13:2<133::AID-PTR398>3.0.CO;2-O. PMID 10190187.
2. ↑ Clark D, Adams M. (2007). "Using commercial nutraceutical mixes as immune stimulants: an in vitro proliferation study using Metabolic Cell-Support on non-stimulated human lymphocytes". Austr. J. Med. Herbal. 19: 108–111.
3. ↑ Ng ML, Yap AT. (Oct 2002). "Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes)". J Altern Complement Med. National University of Singapore. 8 (5): 581–9. doi:10.1089/107555302320825093. PMID 12470439.
4. ↑ Yang P, Liang M, Zhang Y, Shen B. (Aug 2008). "Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC". Adv Ther. 25 (8): 787–94. doi:10.1007/s12325-008-0079-x. PMID 18670743.CS1 maint: Multiple names: authors list (link)
5. ↑ Nimura H, Mitsumori N, Takahashi N, (Jun 2006). "[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]". Gan to Kagaku Ryoho. 33 (1): 106–9. PMID 16897983.CS1 maint: Multiple names: authors list (link)
6. ↑ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. (1999). "A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group". Hepatogastroenterology. 46 (28): 2662–8. PMID 10522061.CS1 maint: Multiple names: authors list (link)
7. ↑ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (July 2009). "Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer". Anticancer Res. 29 (7): 2739–45. PMID 19596954.CS1 maint: Multiple names: authors list (link)
8. ↑ Hazama S, Watanabe S, Ohashi M; et al. (July 2009). "Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta}-1,3-Glucan) for the Treatment of Advanced Colorectal Cancer". Anticancer Res. 29 (7): 2611–7. PMID 19596936.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
9. ↑ Kataoka H, Shimura T, Mizoshita T; et al. (2009). "Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life". Hepatogastroenterology. 56 (90): 547–50. PMID 19579640.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
10. ↑ Isoda N, Eguchi Y, Nukaya H; et al. (2009). "Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma". Hepatogastroenterology. 56 (90): 437–41. PMID 19579616.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
11. ↑ Shimizu K, Watanabe S, Watanabe S; et al. (2009). "Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer". Hepatogastroenterology. 56 (89): 240–4. PMID 19453066.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
12. ↑ EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). European Food Safety Authority (EFSA), Parma, Italy (2010), "Scientific Opinion on the safety of "Lentinus edodes extract" (Lentinex®) as a Novel Food ingredient" (PDF), EFSA Journal, 7 (8): 1685, doi:10.2903/j.efsa.2010.1685CS1 maint: Multiple names: authors list (link)

Template:Carbohydrates